Status:

RECRUITING

Effects of Fibres Combined With Probiotics on Uric Acid in an ex Vivo Fermentation Model

Lead Sponsor:

Örebro University, Sweden

Collaborating Sponsors:

University of Copenhagen

Conditions:

Hyperuricemia

Eligibility:

All Genders

18-80 years

Brief Summary

In this study, we will collect faecal samples from individuals with hyperuricaemia (assessed by blood test) and perform in vitro faecal fermentation studies to assess how probiotics in combination wit...

Detailed Description

In this study, the investigators will collect blood samples to check if recruited participants have hyperuricemia, and if yes, stool samples will be collected for laboratory faecal fermentation tests....

Eligibility Criteria

Inclusion

  • Signed informed consent prior to any study-related procedures
  • Age 18-80 years old
  • BMI range 18.5-35 kg/m2
  • Blood uric acid above 0.36 mmol/L (6 mg/dl)
  • Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages), until collection of faecal material
  • Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study, until collection of faecal material

Exclusion

  • Diagnosis of type 1 and/or type 2 diabetes
  • Diagnosed inflammatory bowel disease (IBD)
  • Current diagnosis of psychiatric disease/s or syndromes
  • Current diagnosis of neurodegenerative disease
  • Current pregnancy or breastfeeding
  • History of complicated gastrointestinal surgery
  • Systemic use of antibiotics and/or steroid medication in the last 4 months prior to inclusion
  • Regular use of any non-steroidal anti-inflammatory drug (NSAID) for the last 2 months
  • Consumption of any NSAID within 3 days of sample collection
  • Current (or within the last 4 weeks prior to study start) use of probiotic supplementation
  • Any condition or intake of medication which could substantially interfere with the outcome of the study, as decided by the principal investigator's discretion
  • After being included in the study and until collection of faecal material, starting any medication or treatment that could potentially influence the study participation and/or study analysis

Key Trial Info

Start Date :

June 12 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2028

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT06981663

Start Date

June 12 2025

End Date

December 1 2028

Last Update

August 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Örebro University

Örebro, Sweden